Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
The DOI matches its Crossref record.
Abstract
As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoproteincholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirmed that LDL-C represents the primary or even the only target of treatment. Yet, increasing evidence suggests moving away from a LDL-C target-based approach to a more tailored treatment approach. For example, non- HDL-C has been introduced in the last few years as a target of treatment. Keywords: Combined dyslipidemia, cholesterol, low-density lipoprotein-cholesterol, small, dense low-density lipoprotein, high-density lipoprotein- cholesterol, non-high-density lipoprotein-cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mohammadi-Sartang, M., Ghorbani, M., & Mazloom, Z. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.11.003 · Cited by 94
Fan, W., Philip, S., Granowitz, C., Toth, P. P., & Wong, N. D. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.11.008 · Cited by 67
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1988568 · Cited by 54
Self-citationPharmacotherapy for gestational diabetes
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1509955 · Cited by 19
Self-citation
Metadata
- Authors
- Rizzo, M., Barylski, M., Rizvi, A. A., Montalto, G., P. Mikhailidis, D., & Banach, M.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-04-01
- Volume
- 19
- Issue
- 21
- Pages
- 3858-3868
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2117051752
- Cited by
- 43
- References
- 0
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia? https://app.cochat.ai/papers/10.2174/13816128113199990324
- The paper
- Rizzo, M., Barylski, M., Rizvi, A. A., Montalto, G., P. Mikhailidis, D., & Banach, M. (2013). Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia? Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.